Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Peptide Receptor Radionuclide Therapy for Metastatic Inoperable Neuroendocrine Tumors Using 177-Lu-DOTA 0, Tyr 3 Octreotate

NCT02125474 is registered in ClinicalTrials.gov with Instituto Nacional de Cancerologia, Columbia as lead sponsor.

NCT NCT02125474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02125474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Peptide Receptor Radionuclide Therapy for Metastatic Inoperable Neuroendocrine Tumors Using 177-Lu-DOTA 0, Tyr 3 Octreotate
Lead sponsor
Instituto Nacional de Cancerologia, Columbia
Phase
Not applicable
Overall status
Completed
Start date
November 30, 2013
Completion date
October 1, 2019
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors